Hormonal therapy is one of the treatment options for prostate cancer patients. There are many hormonal treatments modality to block the testosterone effect on prostate cancer cell proliferation. Degarelix is an innovative molecule able to antagonize the GnRH receptor with comparable oncological results to GnRH agonist, but with less side effects, avoiding the flare up phase, and better efficacy in LUTS relief. These characteristics of degarelix can impact on the clinical decision making to choose a therapy instead of another.
AxcronaK., AaltomaaS., da SilvaC.M., OzenH., DamberJ.E., TankóL.B., ColliE., KlarskovP.. Androgen Deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: degarelix vs goserelin plus bicalutamide.BJU International.2012, 13; 1–8.
2.
Effects of the gonadotropin-releasing hormone antagonist ganirelix on normal micturition and prostaglandin E(2)-induced detrusor overactivity in conscious female rats.RussoA., CastiglioneF., SaloniaA., BenigniF., RigattiP., MontorsiF., AnderssonK.E., HedlundP.. Eur Urol.2011 May; 59(5): 868–74.
Gonadotropin-releasing hormone (GnRH) and GnRH receptor in bladder cancer epithelia and GnRH effect on bladder cancer cell proliferation.BahkJ.Y., KimM.O., ParkM.S., LeeH.Y., LeeJ.H., ChungB.C., MinS.K.. Urol Int.2008; 80(4): 431–8. Epub 2008 Jun 27.
5.
GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males.TanriverdiF., Gonzalez-MartinezD., HuY., KelestimurF., BoulouxP.M.. Clin Exp Immunol.2005 Oct; 142(1): 103–10.
6.
Preoperative erectile function represents a significant predictor of postoperative urinary continence recovery in patients treated with bilateral nerve sparing radical prostatectomy.GandagliaG., SuardiN., GallinaA., CapitanioU., AbdollahF., SaloniaA., NavaL., ColomboR., GuazzoniG., RigattiP., MontorsiF., BrigantiA.. J Urol.2012 Feb; 187(2): 569–74.
7.
LHRH antagonist Cetrorelix reduces prostate size and gene expression of proinflammatory cytokines and growth factors in a rat model of benign prostatic hyperplasia.RickF.G., SchallyA.V., BlockN.L., HalmosG., PerezR., FernandezJ.B., VidaurreI., SzalontayL.. Prostate.2011 May 15; 71(7): 736–47.
8.
Mechanisms of inhibition of human benign prostatic hyperplasia in vitro by the luteinizing hormone-releasing hormone antagonist cetrorelix.SiejkaA., SchallyA.V., BlockN.L., BarabutisN.. BJU Int.2010 Nov; 106(9): 1382–8.
9.
Association between American Urologic Association (AUA) urinary symptom score and disease stage in men with localized prostate cancer.LehrerS., StoneN.N., DrollerM.J., StockR.G.. Urol Oncol.2002 Mar-Apr; 7(2): 73–6.
